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Introduction 
Patient J.D. is a 53 year old man who was recovering 
uneventfully in a coronary care unit 5 days after having an 
acute inferior myocardial infarction. Fifteen seconds after 
being told that his mother died, J.D. developed ventricular 
fibrillation (Fig. 1). 
In this presentation, I discuss concepts that relate to the 
onset of ventricular tachyarrhythmia in patients like J.D. I 
do this by reviewing some of the clinically relevant contri- 
butions made by cardiac electrophysiology and the promises 
that the future offers in understanding and treating patients 
with cardiac arrhythmias. Selected aspects of four areas will 
be discussed: pathogenesis, treatment, prognosis and future 
directions. 
Pathogenesis of Cardiac Arrhythmias 
Mechanisms responsible for cardiac arrhythmias are gen- 
erally divided into three major categories: disorders of 
impulse formation, disorders of impulse conduction and 
combinations of both causes (Table 1) (l-5). The classifica- 
tion is limited and contains some inconsistencies. For exam- 
ple, reentry is not actually a mechanism, but rather is a 
pathway traveled by the cardiac impulse. The mechanism is 
really a circus movement of excitation (2). Abnormalities in 
cell to cell coupling and excitability (6), effects of anisotro- 
phy (7) and other factors are lumped under single, simple 
headings. Nevertheless, it serves as a useful framework in 
which to discuss arrhythmogenesis. 
Disorders of Impulse Formation 
Automaticity, triggered activity and afterdepolarizations. 
Normal automaticity relates to the normal diastolic depolar- 
ization of pacemakers found in the normal sinus node, 
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Purkinje fibers and some other areas in the heart. Abnormal 
automaticity may occur in many of these fibers subjected to 
the effects of ischemia, drugs or other interventions. Both 
normal and abnormal forms of automaticity can generate 
arrhythmias (l-5,8). 
Triggered activity. This concept has been emphasized 
recently (3), though it is not new (9). It refers to a transient 
membrane oscillation triggered by cardiac depolarization. 
When this oscillation occurs early, before repolarization is 
completed, it is called an early afterdepolarization; when it 
occurs late, after repolarization is completed, it is called a 
delayed afterdepolarization (3). Slow heart rates generally 
increase the amplitude of early afterdepolarizations, 
whereas fast heart rates, within limits, increase the ampli- 
tude of delayed afterdepolarizations. In this example of a 
transmembrane cardiac action potential recording (Fig. 2), 
depolarization during the upstroke of the cardiac action 
potential (arrow) corresponds to the QRS complex in the 
scalar electrocardiogram (ECG) (10). During repolarization, 
when the T wave would be present, additional depolariza- 
tions occur (arrowheads). These early afterdepolarizations, 
produced in this example by superfusing an isolated Purkinje 
fiber with cesium, can prolong repolarization (lengthen the 
QT interval in the scalar ECG) and can give rise to prema- 
ture complexes or tachycardia (Table 1) (11-14). 
Afterdepolarizations. Early afterdepolarizations result 
from a reduced repolarizing current in comparison with the 
depolarizing current. This may be caused by a reduced 
outward current, an increased inward current or both (3). 
Because interventions that act through different mechanisms 
can abolish early afterdepolarizations (such as the calcium 
channel blockers, verapamil, D-600 and nitrendipine [ 151; 
the sodium channel blockers like tetrodotoxin and lidocaine 
[16] and increasing rate or increasing external potassium 
[K+]) and because a variety of substances can induce early 
afterdepolarizations (such as quinidine [ 161 and related drugs 
[3], a sea anemone polypeptide [17], calcium current agon- 
ists [18], acidosis [19], low extracellular Kf concentration 
[20], hypoxia and catecholamines), a diversity of currents 
have been suggested as causes. These include a calcium 
current through L-type calcium channels (18), the sodium 
“window” or slowly inactivating current (21), sodium chan- 
nel exchange mechanisms (22), the transient inward current 
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MONITOR 
Figure 1. Monitor recording from patient J.D., showing 
the onset of ventricular fibrillation. 
activated by elevated intracellular calcium (23) intracellular 
potassium accumulation (21) and the I,, current (24). 
Cesium blocks inward-rectifying potassium currents and 
delays repolarization (2.5). However, the ionic basis of 
cesium-induced early afterdepolarizations is still unclear. 
Some early afterdepolarizations may be due to electrotonic 
membrane events (11). A calcium current through L-type 
calcium channels may be involved (l&26). Cesium produces 
early afterdepolarizations in canine cardiac Purkinje fibers 
(10,12) and in the intact heart (lo,1 1). The latter exhibits 
Table 1. Mechanisms of Arrhythmogenesis 
similarities to both the acquired and the idiopathic (congen- 
ital) long QT syndromes (see below). Magnesium suppresses 
these early afterdepolarizations and associated ventricular 
tachyarrhythmias (10,27), possibly by blocking the calcium 
current (28), whereas ansae subclaviae stimulation and nor- 
epinephrine infusion stimulates them. 
Alpha-l adrenoceptor stimulation, by provoking intracel- 
lular calcium accumulation, has been implicated in the 
genesis of ventricular arrhythmias associated with ischemia 
(29). Alpha-l adrenoceptor stimulation has also been shown 
I. Disorders of impulse formation 
A. Automaticity 
I. Normal automaticity 
a. Experimental examples-normal in vivo or in vitro sinus node. Purkinje fibers. others 
b. Clinical examples-sinus tachycardia or bradycardia inappropriate for the clinical situation, possibly 
ventricular parasystole 
2. Abnormal automaticity 
a. Experimental example-depolarization-induced automaricity in Purkinje fibers or ventricular muscle 
b.Clinical example-possibly accelerated ventricular rhythms after myocardial infarction 
B. Triggered activity 
1. Early afterdepolarizations (EADs) 
a. Experimental example-EADs produced by barium, hypoxia. high concentrations of catecholamines. 
drugs such as sotalol. N-acetylprocainamide, cesium 
b. Clinical examples-possibly acquired long QT syndrome and associated ventricular arrhythmias 
2. Delayed afterdepolarizations (DADS) 
a. Experimental example-DADS produced in Purkinje fibers by digitalis 
b. Clinical example-possibly some digitalis-induced arrhythmias 
II. Disorders of impulse conduction 
A. Block 
I. Bidirectional or unidirectional without reentry 
a. Experimental example-SA node, AV node. bundle branch, Purkinje muscle, others 
b. Clinical example--GSA node. AV node bundle branch. others 
2. Unidirectional block with reentry 
a. Experimental examples-AV node, Purkinje muscle junction, infarcted myocardium. others 
b. Clinical examples-reciprocating tachycardia in WPW syndrome. AV nodal reentry, VT due to 
bundle branch reentry, others 
3. Reflection 
a. Experimental example-Purkinje fiber with area of inexcitability 
b. Clinical example-unknown 
III. Combined disorders 
.4. Interactions between autonomic foci 
I. Experimental examples-depolarizing or hyperpolarizing subthreshold stimuli speed or slow automatic 
discharge rate 
2. Clinical example-modulated parasystole 
B. Interactions between automaticity and conduction 
I. Experimental examples-deceleration-dependent block, overdrive suppression of conduction. entrance 
and exit block 
2. Clinical examples-similar to experimental examples 
AV = atrioventricular: SA = sinoatrial; VT = ventricular tachycardia; WPW = Wolff-Parkinson-White 
syndrome. Reproduced with permission from Zipes (176). 
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Figure 2. Transmembrane potential recordings showing the effect 
of magnesium chloride on early afterdepolarizations induced by 
cesium in a spontaneously discharging canine cardiac Purkinje fiber. 
Top, Several repetitive early afterdepolarizations were induced by 5 
mM cesium (Cs) in 2.7 potassium chloride Tyrode’s solution. 
Middle, Five minutes after superfusion with 5 mhl magnesium 
chloride added to the cesium-low potassium Tyrode’s solution, early 
afterdepolarizations were abolished. Bottom, Four minutes after 
washout of magnesium chloride and resumption of superfusion with 
cesium-low potassium Tyrode’s solution, early afterdepolarizations 
recurred. Reproduced with permission from the American Heart 
Association. Inc. t IO). 
to produce delayed afterdepolarizations in Purkinje fibers 
removed from cats with previous myocardial infarction, but 
not in normal feline Purkinje fibers unless the extracellular 
calcium concentration is raised (30). Alpha- 1 adrenoceptor 
stimulation leads to an increase in cytosolic free calcium 
(31), which could increase the net inward current. This 
would magnify the amplitude of early afterdepolarizations 
and exacerbate the prevalence of ventricular tachyarrhyth- 
mias related to them. Alpha-l adrenoceptor blockade might 
be expected to exert opposite effects (32). 
Long QT syndromes. Just as the Wolff-Parkinson-White 
syndrome serves the clinical electrophysiologist as the Ro- 
setta stone of reentry, so may the long QT syndrome be the 
Rosetta stone for an entirely different class of arrhythmias. 
In patients with acquired and idiopathic (congenital) long QT 
syndromes (33,341, early afterdepolarizations may be re- 
sponsible for the prolonged repolarization and the associated 
ventricular arrhythmias such as torsade de pointes (14.35). 
The example illustrated in Figure 3 was recorded in an intact 
dog with use of a special catheter electrode that produces a 
RVMAP 
Figure 3. Recording of monophasic action potential from the right 
ventricle (RVMAP) along with electrocardiographic (ECG) lead II 
and right atrial electrogram (RA). Panel A, Control. No early 
afterdepolarization present. Panel B. Immediately after administra- 
tion of cesium (intravenously). Early afterdepolarization is indicated 
by the arrow. Panel C, After continued administration of cesium. 
premature ventricular complexes and ventricular tachycardia result. 
Note the large early afterdepolarization occurring after a pause in 
the cycle (arrow). 
monophasic action potential (36) resembling the intracellular 
recording in Figure 2. Early afterdepolarizations (Fig. 3, 
arrow) develop shortly after cesium injection. Early after 
depolarizations can occur at a reduced (Fig. 2) or a more 
negative (Fig. 3) membrane potential. When sufficient ce- 
sium is administered, ventricular tachyarrhythmias similar 
to torsade de pointes result. Note the long-short cycle length 
in Figure 3 before the onset of the ventricular tachycardia 
(Fig. 4). Magnesium has been reported to suppress torsade 
de pointes in patients with the acquired long QT syndrome 
due to quinidine and other antiarrhythmic agents (37). It also 
suppresses cesium-induced early afterdepolarizations (Fig. 
2) (10.27) and ventricular tachyarrhythmias in the dog (10). 
Idiopathic long QT syndrome: role of left stellate stimula- 
tion. In patients with the idiopathic long QT syndrome, left 
stellate stimulation, possibly due to sympathetic imbalance, 
has been postulated as a possible cause of ventricular 
arrhythmias (38). This animal model produced by cesium 
administration simulated many aspects of the acquired and 
idiopathic long QT syndromes and provided the opportunity 
to test this hypothesis. We found that dogs treated with 
cesium had larger amplitude early afterdepolarizations and a 
greater prevalence of ventricular tachycardia during left 
stellate stimulation compared with right stellate stimulation 
(Fig. 5) (39). Left sympathetic stimulation may be arrhyth- 
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Figure 4. Polymorphic ventricular tachycardia resembling torsade 
de pointes. The ventricular tachycardia shown during its onset in 
Figure 3 continues as polymorphic ventricular tachycardia resem- 
bling torsade de pointes. Finally, it terminates at the end of the 
continuous recording of electrocardiographic lead II. Reproduced 
with permission from the American Heart Association, Inc. (175). 
mogenic because it exerts a quantitatively greater adrenergic 
influence on the ventricles, particularly the left ventricle, 
than does the right stellate ganglion. We postulate that left 
sympathetic stimulation, which results in a larger ventricular 
mass being affected by more norepinephrine being released, 
rather than qualitative differences between the stellate gan- 
glia or right-left stellate imbalance, may be the basis for the 
arrhythmogenic potential of the left stellate ganglion. It also 
may account for the beneficial effects of surgical interruption 
of the left stellate ganglion. 
One can hypothesize that patients with the idiopathic long 
QT syndrome have a primary myocardial membrane defect 
manifested during repolarization (for example, involving an 
outward repolatizing potassium current or an inward cal- 
cium current) that creates early afterdepolarizations and the 
long QT interval. Autonomic imbalance is not necessary. 
Sympathetic stimulation, primarily left, could periodically 
increase the amplitude of the early afterdepolarizations to 
reach threshold and produce ventricular tachyarrhythmias. 
The fact that left stellate ganglion interruption reduces the 
incidence of syncope and sudden death in some patients with 
the idiopathic long QT syndrome in whom beta-adreno- 
ceptor blocking drugs are ineffective (40) underscores the 
potential importance of alpha-adrenoceptor stimulation of 
early afterdepolarizations (32). In patients with the long QT 
syndrome after surgery, the long QT interval generally does 
not shorten, although ventricular tachyarrhythmias cease, 
possibly because early afterdepolarizations are still present, 
though subthreshold. Left stellate ganglion interruption has 
also been shown to reduce sudden death in patients after 
anterior myocardial infarction (41) and, thus, its stimulation 
may be arrhythmogenic during ischemia in patients like J.D. 
(Fig. 1). 
Causes of delayed afterdepolarizations. Delayed afterde- 
polarizations have been reported (42-44) experimentally in 
Figure 5. Differential response of early after- 
depolarizations during each intervention in 
the same dog. Panel A was recorded during 
control; no early afterdepolarizations or any 
voltage deflections exist during phase 3 or 4. 
One minute after cesium injection, panels B, 
C, D and E were recorded during cesium 
alone (panel B) or with right (RAS) (panel C), 
left (LAS) (panel D) and bilateral (BAS) (panel 
E) ansae subclaviae stimulation. The numbers 
within the monophasic action potential (MAP) 
recordings represent the early afterdepolariza- 
tion amplitude as a percentage of the mono- 
phasic action potential amplitude. Panel F 
shows the effect of left stellate stimulation 
(LAS) on the same dog 25 s after panel D was 
recorded; after an atria1 paced beat, a short run 
of nonsustained ventricular tachycardia (VT) 
occurred. Note the decreased amplitude of the 
early afterdepolarization in the right ventricle 
(RV) compared with the high take-off potential 
of the early afterdepolarization in the left ven- 
tricle (LV), initiating the ventricular tachycar- 
dia. LVMAP = left ventricular monophasic 
action potential recording; -0, -5 indicate 0 to 
5 mV. LVEG = left ventricular electrogram; 
other abbreviations as in Figure 3. Reproduced 
with permission of the American Heart Asso- 
ciation, Inc. (39). 
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several settings, such as in digitalis-treated hearts, during 
catecholamine stimulation of the coronary sinus, sympa- 
thetic neural stimulation and 24 h after myocardial infarction 
in dogs (Table 1). Digitalis poisons sodium-potassium aden- 
osine triphosphate, which leads to an increase in intracellu- 
lar sodium that then exchanges for calcium. The elevated 
intracellular calcium concentration causes more calcium to 
be released from the sarcoplasmic reticulum (calcium- 
initiated calcium release), which triggers a transient inward 
current carried by sodium that causes the delayed afterde- 
polarizations (45). Delayed afterdepolarizations may be re- 
sponsible for some of the clinical arrhythmias that are found 
in situations resembling the experimental conditions in 
which they have been produced (for example. arrhythmias 
due to digitalis or occurring after myocardial infarction). 
Delayed afterdepolarizations could be recorded in endocar- 
dium resected from a patient with recurrent episodes of 
ventricular tachycardia due to coronary artery disease (Fig. 
6) (46). In this example, during initial electrical stimulation 
(filled circles). the preparation developed a gradual increase 
in the amplitude of the delayed afterdepolarizations 
(arrows). The depolarization phase of the action potential is 
not clearly seen because of the rapid upstroke, whereas 
repolarization is obvious. After cessation of stimulation (last 
filled circle), a large delayed afterdepolarization results and 
triggers the sustained short run of spontaneous action poten- 
tials, probably comparable with ventricular tachycardia in an 
intact heart. A subthreshold delayed afterdepolarization 
(arrow) terminates the burst. Accelerated atrioventricular 
(AV) junctional escape complexes may be due to delayed 
afterdepolarizations (47). 
Disorders of Impulse Conduction 
Reentrant tachyarrhythmias. The presence of unidirec- 
tional block is the basis for reentry and has been demon- 
strated experimentally in many preparations, including AV 
node1 tissue, ischemic/infarcted ventricular muscle, the bun- 
dle branches (491, Purkinje-muscle junctions and at other 
cardiac sites (49-52). Determinants of conduction patterns 
that produce reentry are multiple and complex, including 
changes in cellular excitability and cell to cell coupling (6), 
anisotropic propagation (7) and rate of rise of action poten- 
tial depolarization. Calcium concentration (53), pH (54) and 
autonomic influences (55) affect cell to cell coupling, which 
in turn modulates conduction. 
Reentry curt occur over anatomically or functionally 
dejined pathways and is basically of three types: 1) reentrant 
circuits created by separate anatomic pathways, such as in 
the Wolff-Parkinson-White syndrome (56,57); 2) functionally 
determined reentrant circuits without an anatomic obstacle 
(leading circle reentry), such as in some forms of intraatrial 
reentry (51); and 3) anisotropic reentry, recently described in 
ventricular muscle (58). Anisotropic reentry is also func- 
O- 
Xl 
A 
??? ?
Figure 6. Triggered sustained rhythmic activity and delayed after- 
depolarizations in diseased human ventricle. A, Spontaneous activ- 
ity triggered by a series of driven action potentials (dots) at recording 
site X,. Note the gradual increase in the size of the delayed 
afterdepolarizations (arrows) until the afterdepolarization reaches 
threshold and maintains sustained rhythmic activity after cessation 
of pacing. The sustained rhythmic activity finally terminates when 
the last afterdepolarization fails to reach threshold (third arrow). B, 
Initiation of triggered activity by intracellular current injection (dots 
beneath the respective action potential recordings) at sites X, and 
X,, which lie along the same trabeculum. Although sites X, and XI 
were only about 4 mm apart, triggered sustained rhythmic activity 
from one site did not propagate to the other site. indicating complete 
dissociation between these two sites. For current pulses, cycle 
length = 2,000 ms; pulse duration = 10 ms; pulse intensity = 200 na. 
Vertical calibration: 50 mV; horizontal calibration: IO s. Repro- 
duced with permission from Gilmour et al. (46). 
tional and is dependent on myocardial geometry. Conduc- 
tion of the cardiac impulse on a microscopic level is discon- 
tinuous as a result of recurrent changes in resistance to 
propagation. Conduction is several times faster in a direc- 
tional parallel to the long axis of the fiber compared with a 
transverse direction because of better cell to cell coupling 
longitudinally (7). However, the safety factor for conduction 
is lower in a longitudinal compared with a transverse direc- 
tion (that is, conduction block occurring after premature 
stimulation is more likely to occur longitudinally than trans- 
versely). Slow transverse activation can provide the neces- 
sary time for recovery of excitability in previously blocked 
fibers to permit reentry (58). Anistropy can be uniform 
(when fibers are all parallel to each other) or nonuniform 
(when barriers such as nonconductile connective tissue are 
interposed). Nonuniform anisotropy might be particularly 
conducive to the development of reentry because of inho- 
mogeneous activation. 
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Figure 7. Phase-dependent acceleration and delay of Purkinje fiber 
automaticity induced by subthreshold depolarizations. The Purkinje 
fiber was separated into two segments by an inexcitable segment so 
that stimulation of one side produced action potentials that blocked 
at the inexcitable middle segment. However, the middle segment 
acted as a conduit for passive flow of current from right and left 
segments. Thus, action potentials in one (right) segment generated 
an electrotonic potential that produced subthreshold depolarizations 
in the other (left) segment. A, Action potentials were recorded from 
the right (upper recording) and left (lower recording) segments of the 
fiber. The control spontaneous cycle length of the left segment was 
I.500 ms. Stimulation of the right segment of the fiber (arrow) 800 
ms after the left segment had discharged spontaneously produced a 
subthreshold depolarization in the left segment and prolonged the 
cycle length of the next spontaneous discharge (arrowhead) to I .850 
ms (a 23% increase). B, Stimulation of the right segment (arrow) 
I .OOO ms after the left had discharged spontaneously shortened the 
spontaneous cycle length (arrowhead) to 1.230 ms (an 18% 
decrease). C, Complete phase-response curves for the experiment 
shown in A and B. Two different runs are shown. Ordinate: Percent 
increase or decrease in the spontaneous cycle length of the left 
segment (control cycle length = 100%7c). Abscissa: percent of the 
control left segment spontaneous cycle length at which the cycle 
length was stimulated. The spontaneous cycle length was maximally 
prolonged (by 26%) or shortened (by 207~) by subthreshold depo- 
larizations that entered the left segment after approximately 50 and 
60%’ of the cycle had elapsed. respectively. Reproduced with 
permission from the American Heart Association (Jalife J. Moe GK. 
Circ Res 1976:39:801-l?), 
Rejlection (50) is n form of reentry occurring in (I O~CJ- 
dirnensiontd structure. The impulse travels back and forth 
over the same pathway. Clinical arrhythmias due to refec- 
tion have not yet been definitely identified. 
Cornhkd Disorders oj’lrnpulse Forrmtion 
and Conduction 
Most ,llould ngree that the trlchvrrrrhvthmirr dejinitely due Parasystole. The last category of mechanisms deals with 
to reentry in hurnrrns is the AV reentrcrnt rrrchycrrrdin in interactions between automatic foci and conduction. On the 
pufients Mith the Wolf-Parkinson- White syndrome (56). In- basis of experimental and clinical data, an arrhythmia ex- 
terruption of this tachycardia by surgical dissection at widely plained by such interactions is modulated parasystole. Jalife 
separated points in the reentrant loop (that is. at the AV and Michaels (62) have developed phase-response curves for 
node-His bundle or the accessory pathway) provides com- 
pelling evidence to support a reentrant mechanism. Simi- 
larly, clinical and laboratory data (57) point to AV node 
reentrant tachycardia as the tachycardia next most likely to 
be due to reentry. Although many, if not most. atrial and 
ventricular tachycardias (58). flutter and fibrillation are due 
to reentry, normal or abnormal forms of automaticity or 
triggered activity may also be responsible. Therefore, one 
cannot generalize about the mechanism responsible for an 
entire group of arrhythmias such as ventricular tachycardia. 
Reentry and mechanisms of clinical arrhythmias. At 
times. both reentrant and nonreentrant mechanisms may 
operate simultaneously, as shown recently (59) in the cat 
heart after coronary occlusion. Studies based on entrain- 
ment criteria (60). analysis of sites of slow conduction and 
the abolition of tachycardia by relatively discrete ablative 
shocks (61) offer strong but circumstantial evidence for 
reentry as a cause of many clinical arrhythmias. Conclusions 
about mechanisms of arrhythmias derived from interpreta- 
tions of the scalar ECG or even from intracardiac catheter 
electrode recordings, response of the arrhythmia to drugs 
assumed to exert selective actions on automaticity or con- 
duction and to electrical stimulation must be made cau- 
tiously. When one is investigating an arrhythmia originating 
in a small reentrant island lost in a large sea of myocardium, 
accurate charting becomes very difficult. 
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Figure 8. Modulation of pacemaker activity by subthreshold cur- 
rent pulses in diseased human ventricle. A, Two recording sites 
along the same trabeculum in a spontaneously active preparation. 
Intervals are in milliseconds. Injection of a subthreshold current 
pulse through the lower microelectrode (dot) early in the spontane- 
ous cycle (about 680 ms after initiation of the rapid portion of the 
preceding action potential upstroke) produced a subthreshold depo- 
larization in the upper recording (arrow) and delayed the next 
spontaneous discharge by 400 to 1,900 ms. This response would fall 
in the first half of the curve indicated in Figure 7. A current pulse 
delivered later in the spontaneous cycle (9.50 ms after the preceding 
upstroke) accelerated the next discharge by 210 to 1,390 ms, relative 
to the previous two action potentials. The response to this current 
injection falls in the second half of the graph depicted in Figure 7. B, 
A stimulus (dot) at a precise interval in the cardiac cycle (called the 
singular point [in this example, 930 ms after the preceding action 
potential upstroke]) abolished pacemaker activity. Reproduced with 
permission from the American Journal of Cardiology (46). 
such parasystolic pacemakers (Fig. 7), which can be applied 
to automatic activity in human ventricular myocardium (Fig. 
8) and to clinical examples of parasystole (Fig. 9). Classi- 
cally, parasystole has been likened to the function of a fixed 
rate, asynchronously discharging pacemaker; its timing is 
not altered by the dominant rhythm, it produces depolariza- 
tion when the myocardium is excitable and the intervals 
between discharges are multiples of a basic interval. Com- 
plete entrance block, constant or intermittent, insulates and 
protects the parasystolic focus from surrounding electrical 
Figure 9. Ventricular parasystole. Measured intervals between pre- 
mature ventricular complexes (indicated in milliseconds). Numbers 
in parentheses indicate multiples of a basic cycle length determined 
as the mean interval between parasystolic discharges. F = fusion 
beat. 
events and accounts for such behavior. Occasionally, the 
focus may exhibit exit block, during which it may fail to 
depolarize excitable myocardium. 
Duta ,from rrcent experiments (62) indicate that these 
“rules” should he modified. The discharge rate of an iso- 
lated “protected” focus can be modulated by electrotonic 
interactions with the dominant rhythm across an area of 
depressed excitability, so that the dominant cardiac rhythm 
(usually sinus) may speed or slow the parasystolic discharge 
rate (63,64). Brief subthreshold depolarizations induced dur- 
ing the first half of the cardiac cycle of a spontaneously 
discharging pacemaker delay the subsequent discharge, 
while similar depolarizations induced in the second half of 
the cardiac cycle accelerate it (Fig. 7 to IO). Fixed coupling 
may be produced, and its presence does not exclude a 
parasystolic mechanism. From these studies, it may be 
inferred that premature ventricular complexes due to para- 
systolic discharge are probably more common than previ- 
ously thought. 
Modulating lnjhences 
All of these electrical events are modulated by a variety 
of other factors, such as the autonomic nervous system, 
hemodynamics and blood flow, chamber geometry and wall 
motion changes (65-68) and effects of ischemia. The latter 
may alter regional myocardial pH, partial pressure of oxygen 
(PO,) and potassium concentrations, and cause the develop- 
ment of lysophosphatides, oxygen free radicals and other 
metabolites that influence electrophysiologic properties. In 
this presentation, I will consider interactions between ische- 
mia and the autonomic nervous system. 
Ischemia and the autonomic nervous system. Although it 
is clear that the autonomic nervous system influences the 
development of cardiac arrhythmias in the ischemic and 
nonischemic heart, knowledge of the mechanisms by which 
this occurs is still evolving. Myocardial ischemia initiates 
both efferent and afferent autonomic activity that may be- 
come excessive early after myocardial infarction (69,70). 
Afferent activation may result from excitation of sensory 
mechanoreceptors or chemoreceptors, or both, located in 
the ventricular wall. Inferior myocardial ischemia/infarction 
is more prone to activate vagal afferents compared with 
anterior myocardial ischemia, which more commonly pro- 
duces an enhanced adrenergic state (71,72). Sinus tachycar- 
dia and hypertension after anterior myocardial infarction and 
-3030(3x %3=2%9l -3%0(4a %3=%32)- %o-mot3r %3*%%)- %o -367ol4 I %3e%2)----c 960 - 
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Figure 10. Graph of the electrocardiogram in Figure 9 shows mod- 
ulated cycle length changes (A XX) expressed as a percent of the 
pure parasystolic cycle (XX), as a function of the interval between 
the last X discharge and the intervening beat of sinus origin (X-R) 
and in terms of percent XX. Open symbols show data measured 
during sequences X-R-R-X. Closed symbols show data measured 
when two X discharges were separated by three or more R re- 
sponses (that is, X-R-R-R... X). XX represents the mean of all pure 
parasystolic cycles. 
sinus bradycardia or AV node block and hypotension after 
an inferior myocardial infarction are well recognized clinical 
states (Fig. 11). 
Sympathetic stimulation. A large body of experimental 
evidence (73,74) suggests that stimulation of cardiac sympa- 
thetic nerves during myocardial ischemia enhances the de- 
velopment of ventricular arrhythmias, while surgical inter- 
ruption or pharmacologic blockade of efferent sympathetic 
response is antiarrhythmic in most models. Although the 
antiarrhythmic effectiveness of beta-adrenoceptor blockade 
has been established in animals and patients (75), experimen- 
tal data (29,76,77) suggest that alpha-l adrenoceptor block- 
ade also produces important antiarrhythmic effects during 
both coronary occlusion and reperfusion. 
Vugal stimulation. In general, vagal tone is antiarrhyth- 
mic for both supraventricular and ventricular arrhythmias 
(73) due to direct electrophysiologic actions on the heart and 
indirect effects that antagonize sympathetic actions and slow 
the heart rate. Rarely does excessive vagal stimulation 
provoke arrhythmias. Atropine may be arrhythmogenic dur- 
ing acute myocardial ischemia, at least in part as a result of 
an excessive increase in heart rate. 
Autonomic modulation of arrhythmia development can 
be mediated by multiple processes, including direct elec- 
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Figure 11. Long-term electrocardiographic recording in a patient 
with atypical angina. The top channel reflects an inferior lead; the 
bottom channel records an anterior lead. Note progressive ST 
segment elevation in the inferior lead, eventually resembling a 
monophasic action potential (top tracing). Bursts of nonsustained 
ventricular tachycardia result (second tracing). Then, sinus slowing 
and Wenckebach atrioventricular block occur, probably from a 
vasodepressor reflex response elicited by ischemia of the inferior 
myocardial wall (third tracing). In the bottom tracing, both atrioven- 
tricular block and ventricular arrhythmias are apparent. Numbers 
indicate time (for example, 2:37 pm). Reproduced with permission 
from Zipes (176). 
trophysiologic actions on impulse formation or conduction, 
or both, effects on infarct size and ischemic metabolism, 
coronary blood flow, platelet clumping, free radial formation 
and other actions (74). Very likely, antiarrhythmic and 
arrhythmogenic autonomic effects compete. For example, 
sympathetic stimulation might be antiarrhythmic by improv- 
ing contractility and coronary flow in a failing heart, but the 
increases in myocardial oxygen demand may cause some 
cardiac arrhythmias (78). 
Some relevant ischemic animal models. Several interest- 
ing models establishing the importance of autonomic- 
ischemic interactions have been investigated. Skinner et al. 
(79) showed that awake pigs psychologically stressed by 
being unacclimatized to the research laboratory developed 
ventricular fibrillation more often and with less latency after 
coronary occlusion than did pigs adapted to the laboratory 
before undergoing coronary occlusion. Cooling the fronto- 
thalamic brain tracts in the unacclimatized pigs prevented 
ventricular fibrillation. This finding, extrapolated to the 
clinical setting, naturally raises interesting speculations 
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about the arrhythmogenic actions of anxiety during acute 
myocardial ischemiaiinfarction, such as experienced by pa- 
tient J.D. 
In other studies, Schwartz et al. (80) demonstrated that 
reflex vagal responses predicted by tests of baroreflex sen- 
sitivity may protect exercising dogs against the development 
of ventricular fibrillation during acute myocardial ischemia 
superimposed on a subacute myocardial infarction. Dogs 
with less vagal responsiveness were more prone to fibrilla- 
tion. Deconditioning could transfer dogs from the protected 
group to the unprotected group with fibrillation. Appropriate 
changes in the baroflex sensitivity slope also resulted. Con- 
ditioning exercises reversed the process. Preliminary studies 
(81) are underway to investigate the applicability of baroflex 
sensitivity tests in patients. 
Recently, Verrier et al. (82) made the important observa- 
tion that anger in dogs results in a sympathetically mediated 
obstruction of partially constricted coronary vessels, but 
also vasodilation of normal coronary arteries. The vasocon- 
striction can be so intense as to obstruct blood flow com- 
pletely in the affected vessel. Importantly, the ischemic 
response occurred late, after the anger had subsided. Some 
ventricular arrhythmias occurred during the late ischemic 
response. Conceivably, platelet thrombi play a role in the 
development of coronary obstruction in this model (83). 
Such delayed changes may help explain the onset of late 
ventricular fibrillation in patients during the cool-down pe- 
riod after completion of a stress test. Vagal stimulation 
reduced vasoconatriction in dogs, perhaps as a result of a 
reduction in heart rate. Verrier and Lown (84) also reported 
that fear increases plasma epinephrine concentration and 
can result in ventricular arrhythmias that also can be an- 
nulled by increases in vagal tone. 
Effect of ischemia/infarction on autonomic innervation of 
the myocardium. Despite the importance of these and other 
examples, however, significant gaps exit in understanding 
exactly how changes in autonomic action influence ischemic- 
related arrhythmias in the intact heart. This gap, at least in 
part, is explained by the generally overlooked concept that 
ischemia/infarction might directly alter autonomic innerva- 
tion (that is, in addition to the afferent reflexes triggered by 
the ischemia and the induced efferent neural discharge, the 
area of ischemiaiinfarction may directly alter neural func- 
tion). A parallel can be found in the ischemia-induced 
changes of cellular myocardial electrophysiologic proper- 
ties. Loss of membrane potential, reduced conduction ve- 
locity and excitability and increased electrical resistance in 
myocardium subjected to ischemia are some of these well 
characterized alterations (85). However, much less is known 
about the effects of ischemiaiinfarction on autonomic nerves 
located in the ischemic region of the myocardium and. if 
changes in the nerves occur, what functional consequences 
they exert (86). 
AS an example. cats with healed myocardial infarction 
EP(CAADUM 
Figure 12. Schematic representation of the functional pathways of 
afferent and efferent sympathetic and vagal innervation to the 
ventricle. Impulses in afferent pathways travel apex-to-base, 
whereas impulses in efferent pathways travel base to apex. Filled 
circles indicate nerve endings. Reproduced with permission from 
Grune & Stratton. Inc. (177). 
exhibit some myocardial areas with enhanced refractory 
period shortening during bilateral sympathetic stimulation, a 
form of supersensitivity (87). Alpha-l (76) and beta- 
adrenoceptor (88) density may increase. One study (89) 
shows no change in beta-adrenoceptor density. Cardiac 
tissue subjected to ischemia may respond differently to 
autonomic impulses; for example, Purkinje fibers from in- 
farcted hearts may develop delayed afterdepolarizations and 
triggered activity during alpha-adrenoceptor stimulation not 
seen in normal Purkinje fibers (44). 
We hule Jbund (90-93) that trunsmurul myocurdial in- 
farction produces efferent sympathetic and vagal denerva- 
tion in the area of the infarction and at noninfarcted sites 
apical (distal) to the infarction. A subendocardial infarction 
that spares the epicardium does not interrupt sympathetic 
transmission, but does interrupt the vagal response because 
sympathetic fibers are located in the subepicardium and 
vagal fibers in the subendocardium (Fig. 12). Neural respon- 
siveness becomes attenuated or lost within minutes after the 
onset of ischemia (93). The mechanism responsible for such 
early changes may relate to the cumulative effects of hyper- 
kalemia, hypoxia, acidosis and other substances generated 
by the ischemic myocardium within which the nerves lie 
(94). After denervation, the myocardium may develop de- 
nervation supersensitivity (91) and subsequent reinnervation 
(Fig. 13) (95). and these changes may be responsible for 
some cardiac arrhythmias (92). Preliminary findings (96) 
obtained with imaging techniques suggest that similar dener- 
vation occurs in the ventricles of patients after myocardial 
infarction. 
Although it is quite clear that ischemiu muy generate 
gfferent cardk reflexes, ischemiu clnd infarction may also 
interrupt afferent reflexes within minutes of its onset (97,98). 
Transient ischemia may reversibly interrupt afferent reflexes 
(98). an observation that may have important clinical impli- 
cations. Because afferent sympathetic fibers appear to me- 
diate cardiac pain (99,100), interruption of afferent neuro- 
transmission by ischemia could eliminate pain perception. 
Thus, painless ischemia or infarction might be explained by 
a type of transient (or permanent) “autodenervation” in- 
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Figure 13. Schematic representation of a canine model of ischemicl 
infarction-induced autonomic denervation. Myocardial infarction is 
indicated by finely stippled area. Bipolar electrodes (solid circles) are 
positioned to measure changes in ventricular effective refractory 
period during neural stimulation in normally innervated regions 
above (basal to) and in denervated regions below (apical to) the 
infarction. A0 = aorta; LCX = left circumflex coronary artery; 
LA = left atrium; LAD = left anterior descending coronary artery; 
LV = left ventricle; PA = pulmonary artery; RA = right atrium; 
RV = right ventricle. During testing of afferent reflexes, pieces of 
gauze soaked in bradykinin or nicotine are applied at the electrode 
sites shown. 
duced by ischemia/infarction. After restoration of flow, 
normal neural function could return (98). 
Therapy of Cardiac Arrhythmias 
Therapy of cardiac arrhythmias can be divided into three 
major categories: pharmacologic, electrical and surgical. 
Pharmacologic Therapy 
Choice of drugs. Although many new antiarrhythmic 
drugs are now available and more are forthcoming (Table 2), 
with few exceptions the actions of most of the new agents 
resemble those of existing drugs such as quinidine and 
procainamide. This is because, in large part, we still do not 
understand how drugs suppress cardiac arrhythmias and, for 
this reason, there is a lack of innovative approaches to 
develop new drugs. At present, we determine the properties 
of antiarrhythmic drugs rather than their antiarrhythmic 
properties. Then, on the basis of of our understanding of the 
mechanisms responsible for cardiac arrhythmias, we predict 
cardiac responses and drug actions that we believe should be 
antiarrhythmic. Because drugs may be effective through a 
myriad of direct and indirect actions, it is difficult in the 
intact at-rhythmic heart to determine antiarrhythmic mecha- 
nisms. 
Despite the lengthy list of new antiarrhythmic agents 
(Table 2), the choice of drug, particularly for treating pa- 
Table 2. Classification of Antiarrhythmic Drugs 
Class I. Drugs that block the fast sodium current 
A. Drugs that reduce Vmax and prolong repolarization and 
refractoriness 
1. Quinidine 
2. Procainamide 
3. Disopyramide 
B. Drugs that usually produce less reduction of Vmax and 
shorten repolarization and refractoriness 
1. Tocainide 
2. Mexiletine 
3. Phenytoin 
4. Lidocaine 
5. Ethmozine 
C. Drugs that reduce Vmax, primarily slow conduction and may 
prolong repolarization and refractoriness minimally 
1. Flecainide 
2. Encainide 
3. Lorcainide 
4. Propafenone 
Class II. Drugs that block beta adrenoreceptors 
A. Propranolol 
B. Timolol 
C. Atenolol 
D. Metoprolol 
E. Others 
Class III. Drugs that block potassium channels and prolong repolarization 
and refractoriness 
A. Sotalol 
B. Amiodarone 
C. Bretylium 
Class IV. Drugs that block the slow calcium channel 
A. Verapamil 
B. Nifedipine 
C. Diltiazem 
tients with ventricular arrhythmias, remains empiric and is 
often made on the basis of the drug’s side effect profile rather 
than any degree of difference in efficacy. Selection of drugs 
to treat supraventricular tachycardias can be predicated on 
our knowledge of the mechanism of the arrhythmia to a 
much greater degree than can the choice of drugs to treat 
ventricular tachyarrhythmias. Further, the drug classifica- 
tion currently used (101,102) has many problems (103) and 
may provide little help in drug selection. 
Modulated receptor hypothesis. Nevertheless, significant 
progress has been made in understanding how drugs affect 
cardiac tissue. The discussion that follows deals with several 
aspects, beginning with the modulated receptor hypothesis 
(104). 
Most antiarrhythmic drugs interfere with the passage of 
ions such as calcium, sodium or potassium across the cell 
membrane. Drugs affect passive membrane properties as 
well, but much less is known about this area. Let us consider 
the sodium channel, which is responsible for the depolariza- 
tion phase of normal atria1 and ventricular muscle and of the 
His-Purkinje system. Drugs gain entry to sarcolemmal chan- 
nels where they bind in or near the channels only during 
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Figure 14. Schematic illustration of the time-dependent changes in 
sodium (Na) channel states, rested (R), open (0) and inactivated (I), 
associated with cardiac action potentials (top) and the resulting 
changing level of sodium channel block (bottom) by a local anes- 
thetic-type antiarrhythmic drug. Note that this drug causes some 
block during the open channel state (upstroke of the action poten- 
tial) and additional block during the inactivated state (plateau). 
During diastole. partial recovery from block occurs because the 
affinity of the drug for the channel is low. Reproduced with 
permission from Anesthrsiology (178). 
certain phases of the action potential, such as when the 
channel gates are cycled or used (use dependence) and when 
they are in an inactivated state (voltage dependence). There- 
fore, the drug would exert greater inhibitory effects on the 
sodium channel and on the upstroke of the action potential at 
more rapid rates of stimulation and after longer periods of 
stimulation. As a result, depression of the upstroke would be 
greater after an action potential depolarization rather than 
after a rest period. This effect might be due to preferential 
interaction of the antiarrhythmic drug with either the open or 
the inactive channel and little interaction with the resting 
channels of the quiescent cell. With increased time spent in 
diastole (slower rate), a greater proportion of receptors 
become drug-free and the drug exerts less effect. Agents in 
class IB (Table 2) exhibit rapid kinetics of onset and offset or 
use-dependent block of the fast channel (that is, they bind 
and dissociate quickly from the receptors). Class IC drugs 
have slow kinetics. and class IA drugs have intermediate 
kinetics (104). 
Figuw 14 illustrates this concept of drug kinetics. During 
depolarization, the sodium channels are open, depicted by 
the 0. During repolarization (plateau of the action potential). 
the sodium channels are in an inactive state (I), and in late 
diastole. they are in a rest state (R). In this example, the drug 
binds to. and thus blocks. some of the sodium channels 
during the open state, and more during the inactive state. 
Drug dissociates from the channels during the rest state. In 
the bottom portion of the tracing, the percent of drug-free 
sodium channels is shown. From this example, one would 
predict that as the heart rate increased and diastole short- 
ened much more than did the action potential duration, the 
drug would have less opportunity to dissociate from the 
sodium channel. Thus, at a more rapid rate, more sodium 
channels would be blocked by the drug. Because sodium 
conductance is a major determinant of conduction velocity, 
the drug may be expected to produce greater slowing of 
conduction at faster heart rates. This type of rate or use 
dependency has now been established for a variety of 
antiarrhythmic agents, and may explain why some drugs 
may be more effective at suppressing rapid than at suppress- 
ing slower tachyarrhythmias (104). 
Quiuitlinc mtl procrrinamidr hm~ thr highest r@nitic)s 
ji~r tllc trcti\wttd state rrd. thcwfow, prirntrrily block the 
sodium chrrnncls \l)hen they rw open. Lidocaine. mexiletine 
and tocainide have the highest affinities during the inacti- 
vated state and, therefore, preferentially block sodium chan- 
nels when they are closed. The short action potential dura- 
tion of atrial muscle cells has a relatively short inactivated 
state. and this fact explains, in part. why the class IB agents 
normally exert little effect on atrial arrhythmias. Quinidine, 
acting primarily on the activated state. affects both atrial and 
ventricular action potentials. Lidocaine and related drugs 
also shorten action potential duration by increasing potas- 
sium conductance or by decreasing the sodium residual or 
window current. Shortening action potential duration short- 
ens the duration of the inactivated state and the opportunity 
for the drug to produce inactivation state-dependent block of 
the sodium current. 
Drug interactions. Many other important aspects of anti- 
arrhythmic therapy have been studied in the past several 
years, such as the interactions among drugs. Simultaneous 
administration of two antiarrhythmic drugs may result in 
additive or inhibitory interactions, depending on the drugs. 
Interactions are often predictable from the modulated recep- 
tor hypothesis. As an example. the efl’ect of a drug with a 
high affinity for the inactivated state can be potentiated by 
another drug that increases the duration of the inactivated 
state (that is. lengthens the plateau of the action potential) 
(104). It was recently shown (105) that a metabolite of 
lidocaine. glycylxylidide, can displace the parent drug from 
the receptor. We also know that one drug can alter the rate 
of metabolism and elimination of another drug to increase or 
decrease dose requirements (Table 3) (106). 
Drug metabolites. Some drugs such as encainide and 
procainamide have active metabolites. The drugs undergo 
extensive hepatic metabolism that produces altered com- 
pounds with electrophysiologic actions that may be the same 
or different from those of the parent compound (107-109). 
We also know that many drugs are metabolized according +o 
genetically determined metabolic pathways. For example, 
5’4 to IO% of the North American and European white 
population have difficulty hydroxylating debrisoquine, an 
antihypertensive drug (I IO). The defect is inherited as an 
autosomal-recessive trait in which patients lack a specific 
cytochromeJ’450 enzyme because of incorrectly spliced 
messenger ribonucleic acids (RNAj) (I I I). Lack of this 
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Agents 
Phenytoin 
Phenobarbital 
Rifampin 
Cimetidine 
Amiodarone 
Digoxin 
Table 3. Pharmacokinetic Interactions of Antiarrhythmic Drugs 
Effects 
Increases clearance of 
Quinidine 
Disopyramide 
Mexiletine 
Digitoxin 
Reduces clearance of 
Quinidine 
Lidocaine 
Procainamide 
Flecainide 
Ethmozin 
Reduces clearance of 
Warfarin 
Phenytoin 
Quinidine 
Procainamide 
Digoxin 
Clearance reduced by 
Quinidine 
Verapamil 
Amiodarone 
Volume of distribution reduced by 
Quinidine 
Lidocaine Clearance reduced by 
Propranolol 
Cimetidine 
Reproduced with permission from Roden (106). 
enzyme affects the metabolism of several antiarrhythmic 
drugs, such as encainide and propafenone, some beta- 
blockers and other commonly prescribed drugs (110). Pa- 
tients may be at high risk for developing adverse drug effects 
because they do not metabolize the drug as rapidly as the 
rest of the population and, therefore, may require less drug 
than the remaining 90% of the population to achieve the 
same pharmacodynamic end point. In contrast, if a major 
drug action is due to the effects of an active metabolite, with 
ordinary drug doses these patients may not develop suffi- 
cient concentrations of the metabolite to achieve a therapeu- 
tic response (106). 
Surgical Therapy 
Drugs remain the mainstay of antiarrhythmic therapy. 
However, drug therapy is frequently not well tolerated or is 
ineffective, particularly in patients with life-threatening ven- 
tricular tachyarrhythmias and reduced ventricular function. 
For many of these patients, selection of nonpharmacologic 
approaches alone or in combination with drugs may be 
preferable. 
Patients with supraventricular arrhythmias and accessory 
pathways. The use of surgery to treat cardiac arrhythmias 
has become increasingly popular in the last decade (112- 
114). The goal of surgery is to isolate, excise or otherwise 
interrupt tissue critical for the initiation or maintanence of 
the tachycardia, while at the same time preserving or im- 
proving myocardial function. Successful surgery provides a 
cure for the patient with a cardiac arrhythmia, in contrast to 
drug therapy, which just keeps the arrhythmia suppressed. 
Candidates are patients who have symptomatic recurrent 
tachyarrhythmias despite adequate drug treatment or pa- 
tients who are not candidates for long-term drug therapy. 
Patients with the Wolff-Parkinson-White syndrome serve as 
the prototypical example of an arrhythmia treated admirably 
with surgery. Interruption of the accessory pathway with use 
of an endocardial (112,114) or epicardial (113,115) approach 
(Fig. 15) achieves a cure rate exceeding 95%, with a mortal- 
ity approaching zero. Surgery for patients who have AV 
node reentrant tachycardia is relatively new, but initial cure 
rates are similar to that for surgery for the Wolff-Parkinson- 
White syndrome (116,117). 
Patients with ventricular tachyarrhythmias. Surgery for 
patients with ventricular tachyarrhythmias has similarly 
improved (113,114,118,119). Candidates include patients 
with recurrent sustained symptomatic ventricular tach- 
yarrhythmias despite adequate drug treatment or those who 
are not candidates for long-term drug therapy. For patients 
with coronary artery disease, electrophysiologically guided 
surgery appears preferable to blind resection and involves 
resection, isolation or ablation of ventricular tissue (gener- 
ally endocardium) involved in the tachycardia (Fig. 16). 
Success rates judged by prevention of a symptomatic recur- 
rence of the arrhythmia with or without drug treatment 
generally range between 70% and 80% (119). However, the 
perioperative mortality rate is still relatively high, about 
15%. Surgery for patients with ventricular tachyarrhythmias 
unassociated with coronary artery disease depends on the 
type of heart disease. Mapping the location of the ventricular 
arrhythmia is mandatory for these patients. 
Electrical Therapy 
Devices. The automatic implantable cardioverterldefibril- 
lator (AICD) is the only implantable device commercially 
available in the United States that electrically cardioverts or 
defibrillates ventricular tachyarrhythmias, or both, in pa- 
tients. The AICD is capable of delivering 25 to 35 J shocks 
and recycling three additional times after the first initial 
shock. Its projected life span is about 2 years (or 100 shocks) 
(120-122). Lower energy shocks in the range of 2 J have been 
used for transvenous cardioversion of ventricular tachycar- 
dia, but are inadequate without backup defibrillation capa- 
bilities (123,124). 
Indications. Patients considered for device implantation 
are those resuscitated from ventricular fibrillation in the 
absence of acute myocardial infarction or other disorders 
with a remedial cause. These patients have ventricular 
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tachyarrhythmias inducible electrically or that occur spon- 
taneously despite drugs or surgery, or both. Some may still 
be candidates who do not have inducible ventricular tach- 
yarrhythmias. Patients who have hypotensive episodes of 
sustained ventricular tachycardia in the absence of acute 
myocardial infarction or a remedial cause and whose ven- 
tricular tachycardia remains inducible despite drug treat- 
ment or surgery, or both, are also candidates (121,122). 
Patients for whom the device may be indicated include 
those with unexplained syncope who have inducible ventric- 
ular tachyarrhythmias causing syncope despite drug treat- 
ment, those with a family history of sudden cardiac death 
associated with entities such as hypertrophic cardiomyopa- 
thy and those who have unexplained syncope with the long 
QT syndrome. 
Contruindications to AlCD implantation. These include 
patients who, despite drug treatment, have very frequent 
episodes of sustained or nonsustained supraventricular or 
Figure 16. Surgery for ventricular tachycardia 
in patients with coronary artery disease. Top 
left, Aneurysm resection alone, which leaves 
the arrhythmogenic tissue untouched (small cir- 
cle with arrow). Bottom left, Endocardial 
(ENDO) ventriculolomy, which isolates the 
arrhythmogenic tissue from the rest of the ven- 
tricle. Top right, Endocardial resection, which 
eliminates aneurysm and arrthythmogenic myo- 
cardium. Bottom right, Cryoablation, which ab- 
lates or isolates arrhythmogenic tissue. EPI = 
epicardium. 
Figure 15. Schematic diagram illustrating the surgical technique for 
dissection at the atrioventricular groove (left panel), using an epi- 
cardial approach with cryoablation (middle panel) and an endocar- 
dial dissection (right). AP = accessory pathway; C.A. = coronary 
artery; C.S. = coronary sinus. 
ventricular tachycardia causing frequent device discharge, 
patients with a short projected life span because of heart 
failure, cancer, or other diseases, psychological reluctance 
to accept the device or a slow ventricular tachycardia 
(usually < 140 beatslmin) (121). 
Selection qf putients and follow-up. Prospective patients 
should undergo cardiac catheterization to determine whether 
concomitant surgery is necessary, an electrophysiologic 
study to establish device applicability, safety and efficacy 
and extensive in-hospital monitoring. Implantation is gener- 
ally by sternotomy, left thorocatomy, subxiphoid or subcos- 
ANEURYSM 
ENCKXIARDIAL 
END0 n 
A ENO~CARDIAL 
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Figure 17. Schematic diagram illustrating electrode sites for non- 
thoracotomy implantation of a cardioversion-defibrillation device. 
Electrodes can be placed in the superior vena cava (SVC), coronary 
sinus (CS) and right ventricular apex (RV). An additional cardiac 
electrode can be placed subcutaneously over the region of the 
cardiac apex. Leads are connected to the pulse generator (PG). At 
the present time, the size of the pulse generator precludes its 
subclavicular placement and requires implantation in the abdominal 
wall. SQ = subcutaneous electrode. 
tal approach. Transvenous approaches are evolving (Fig. 
17). Concomitant coronary artery bypass grafting, endocar- 
dial resection for ventricular tachycardia or other surgical 
procedures may be performed. 
In a long-term follow-up study (121) of270 patients with 
the AICD, actuarial mortality of sudden cardiac death was 
approximately 0.9% at 1 year and 4.4% at 5 years. Compli- 
cations included inappropriate shocks (20%), lead problems 
(1% to 2%), infection (<2%), operative death (~3%) and 
elevated defibrillation thresholds (~2%). 
Future devices. Devices are being developed that will be 
able to deliver sequential shocks (125,126), shocks with a 
biphasic wave form, shocks at multiple programmable en- 
ergy levels, pacing for bradyarrhythmias or tachyarrhyth- 
mias and extensive monitoring capabilities. One such device 
is a multiprogrammable pacemaker-cardioverter-defibrillator 
with telemetry that can be used for bradycardia (VVI) 
pacing, competitive antitachycardia pacing, low energy syn- 
chronous cardioversion and high energy asynchronous defi- 
brillation. The purpose of this device is to deliver staged 
electrical therapy that escalates in intensity according to 
programmable steps in response to the underlying cardiac 
rhythm. With the device’s external programmer, one can 
perform noninvasive electrophysiologic studies. Impor- 
tantly, it has extensive recording capabilities and can store 
the number of episodes of ventricular tachycardia and fibril- 
lation, types of therapy delivered and response to therapy, 
as well as 20 cycle lengths preceding and 10 cycle lengths 
following delivery of therapy. 
Ablation. Supraventricular tachyarrhythmias. Another 
form of electrical therapy for arrhythmias is the use of 
ablation techniques employing a catheter electrode con- 
nected to an energy-delivering source, such as a defibrillator 
(127,128). Capacitor discharge creates a high energy shock 
delivered over the catheter electrode, which can destroy 
areas of the heart involved in the genesis or maintenance of 
a tachyarrhythmia or interrupt conduction in the AV node- 
His bundle in patients with recurrent rapid supraventricular 
tachycardia. Figure 18 illustrates the creation of heart block 
in a 22 year old patient with a 6 year history of recurrent 
exercise-related atria1 tachycardia, flutter and fibrillation. 
Ventricular rates of 200 to 250 beatsimin (in the absence of 
an accessory pathway) could not be slowed despite exten- 
sive pharmacologic trials, including amiodarone. After cre- 
ation of heart block and implantation of an activity-sensing 
pacemaker, the patient became asymptomatic. Although he 
has a new disease (heart block and pacemaker dependency), 
it is clearly preferable to his pre-existing problem. 
Ventricular tachyarrhythmias. The rate of successful 
creation of partial or complete heart block in patients with 
supraventricular tachycardia approaches 90%, whereas 
~50% of patients with ventricular tachycardia are treated 
successfully by catheter ablation (129,130). Success has 
been higher in some series (131). Recently, ablation of the 
right bundle branch has been shown to eliminate ventricular 
tachycardia in patients with bundle branch reentry (49). A 
2% late sudden death rate occurs in patients after creation of 
heart block and pacemaker implantation (129). The sudden 
death may be due to the patients’ intrinsic disease or 
possibly to the ablation procedure. 
Electrical mhlation for patients with Wolff-Purkinson- 
White syndrome (132) and atria1 tuchyarrhythmias is still 
evolving. Radiofrequency (133) and laser (134) ablation 
techniques are undergoing investigation and may become 
practical in the future (135). 
Prognosis 
There has been much progress in improving the ability to 
establish the prognosis of patients with ventricular arrhyth- 
mias using noninvasive and invasive techniques. 
Noninvasive Techniques 
Electrocardiographic signal averaging. Noninvasive as- 
sessments demonstrate that suppression of spontaneous 
ventricular arrhythmias occurring at rest or during exercise 
by an antiarrhythmic drug indicates a better prognosis com- 
pared with lack of suppression (136). Signal averaging ap- 
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Figure 18. Electrode catheter ablation of atrioventricular (AV) con- 
duction and ventricular tachycardia. Panel A, top, Leads I, II, III 
and V, and a His bundle electrogram (HBE) during sinus rhythm 
before the delivery of the shock. Amplitude of the atria1 and His 
bundle electrogram is given. At the dark vertical line in the top right 
panel, 200 joules are delivered between the cathodal electrode 
situated at the His bundle and an anodal patch on the patient’s back. 
In the bottom of panel A, the rhythm immediately after the shock is 
displayed. The patient is now pacemaker-dependent; turning off the 
pacemaker for 5.4 s illustrates underlying complete AV heart block. 
AVN = atrioventricular node; HRA = high right atrial electrogram 
recording; RV = right ventricular electrogram recording; S = 
stimulus. Panel B illustrates an attempt at ablation of ventricular 
tachycardia with the site of origin located near the apical portion of 
the interventricular septum. The first of several lOOjoule shocks was 
delivered between the anodal electrode placed in the left ventricular 
apex and the cathodal electrode placed in the right ventricular apex. 
The delivery of the shock in the top right is reproduced in the bottom 
left of the panel. The ventricular tachycardia is terminated, and the 
CONTROL SCHEMA 
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Figure 19. Ischemic-induced conduction delay. Electrode record- 
ings are obtained in this open chest anesthetized dog from a normal 
zone (NZ) and ischemic zone (IZ) in the left ventricular myocar- 
dium. During ischemia, the ischemic zone electrogram recording 
demonstrates significant conduction delay. which continues past the 
QRS complex and into the ST segment and T wave. 
pears to improve the predictive accuracy of noninvasive 
testing (137,138). It is a technique used to amplify electrical 
signals from the heart that have a voltage that is too small to 
be recorded in the standard scalar ECG (139,140). lschemia 
and infarction can cause marked slowing of conduction that 
results in delayed electrical activity that can be recognized in 
the terminal portion of the QRS complex or early portion of 
the ST segment (Fig. 19) (141). This fragmented low ampli- 
tude cardiac electrical activity may be the electrical event 
recorded in the signal-averaged ECG and may identify 
patients at risk for developing ventricular tachycardia (137- 
140). 
In Figure 20 (137), the QRS complex has been amplified 
by signal averaging. In the top panel, the QRS duration is not 
prolonged and the voltage in the last 40 ms of the QRS 
complex is still very large (that is, 95 PV). In the middle 
panel, note the fragmented and low amplitude potentials 
recorded in the terminal portion of the QRS complex (shaded 
area), prolonging its duration. The voltage of these late 
potentials recorded during the last 40 ms of the QRS com- 
plex is only 4 PV. In the bottom panel, the QRS duration is 
also prolonged, and the voltage in the terminal portion is in 
the range of 14 pV. In this study (137), the presence of 
spontaneous ventricular ectopic activity. abnormal late 
potentials and reduced ejection fraction each contributed 
independently to the prognosis of patients after their recov- 
ery from acute myocardial infarction. Patients who had all 
three risk factors had an event rate of 50% for experiencing 
sustained ventricular tachycardia or sudden death within 1 
year. Patients who had a normal ejection fraction with 
abnormal late potentials or patients who had no late poten- 
tials and a reduced ejection fraction had a better prognosis. 
patients’ dual chamber pacemaker paces the atrium and then the 
ventricle after a slight pause. The electrogram recording at the left 
ventricular apex occurred 40 ms in advance of the onset of the QRS 
complex (not shown). CONT. = control; LV = left ventricle; RV = 
right ventricle; RV,, = right ventricular electrogram recorded at the 
apex. Reproduced with permission from Zipes (179). 
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Figure 20. Signal-averaged electrocardiograms. Top panel, Signal- 
averaged electrocardiogram of a patient with a history of a myocar- 
dial infarction, but no subsequent arrhythmic event. The duration of 
the signal-averaged QRS complex is normal (97 ms), with normal 
duration of terminal signals ~40 FV (6 ms) and a normal root mean 
square (RMS) voltage of the terminal 40 ms (95 pV). The patient had 
an abnormal ejection fraction (EF) of 29% and high grade ventricular 
ectopic activity (HGE+). Middle panel, Signal-averaged electrocar- 
diogram of a patient with anterior wall myocardial infarction and 
documented sustained ventricular tachycardia during follow-up 
study. The QRS duration is prolonged (132 ms), as is the duration of 
low amplitude signals that were ~40 FV (57 ms) (shaded area). The 
root mean square voltage of the terminal 40 ms (4 PV) was 
abnormal. Ejection fraction was reduced (14%) and high grade 
ventricular ectopic activity was present. Bottom panel, The patient 
had inferior myocardial infarction and ventricular fibrillation during 
follow-up study. The QRS duration was normal (113 ms), but there 
was abnormal duration of the low amplitude signal that was ~40 PV 
(42 ms) (shaded area). The root mean square voltage of the terminal 
40 ms (14 pV) was abnormal. Ejection fraction was 41% and high 
grade ventricular ectopic activity was present. Reproduced with 
permission from Gomes et al. (137). 
Invasive Techniques 
Electrophysiologic study. Therapy can be selected and 
prognosis predicted according to the results of an elec- 
trophysiologic study (142-144). In general, when a drug 
prevents electrical induction of a tachycardia initiated in a 
control state, the drug will be highly successful in preventing 
spontaneous occurrences of the tachycardia. Reinitiation of 
the tachycardia during drug therapy does not mean that the 
patient will necessarily experience a recurrence, but makes 
such a recurrence much more likely. Importantly, recent 
data (145) suggest that the hemodynamic consequences of 
the spontaneous recurrence will resemble the patient’s he- 
modynamic response to the laboratory-induced event. Thus, 
if the tachycardia remains electrically inducible but the drug 
slows the rate so that the patient tolerates the arrhythmia, 
the patient may similarly survive spontaneous recurrent 
arrhythmias equally well. 
Invasive versus noninvasive assessment. A comparison of 
an invasive and noninvasive assessment is underway (Mason 
J, personal communication). In one study (143) of patients 
who had recurrent ventricular tachycardia, prognosis was 
predicted more accurately by the results of an electrophys- 
iologic study than by the results of a noninvasive approach. 
In example shown in Figure 21, patients who were predicted 
to be arrhythmia-free by an electrophysiologic study had a 
much better prognosis for recurrence of ventricular tachy- 
arrhythmia than did patients who were predicted to be 
arrhythmia-free by a noninvasive approach (143). However, 
existing data suggest that both approaches have merit and, in 
the final analysis, they test different phenomena. Theoreti- 
cally, noninvasive assessments test for the presence of a 
trigger to start the arrhythmia and the myocardial substrate 
to maintain it. In an electrophysiologic study, the trigger 
(premature electrical stimulation) is supplied and the pres- 
ence of a substrate is tested. An effective drug that only 
eliminated the trigger might fail to prevent electrical induc- 
tion of the tachycardia. Responses from both types of testing 
are important, and together may be more useful than either 
alone in identifying the patient with an acceptable therapeu- 
tic response. 
Future Directions 
Therapy and Prognosis 
New antiarrhythmic agents and drugs for ablation. What 
does the future offer? New antiarrhythmic agents are being 
developed and tested that will increase our capabilities of 
suppressing arrhythmias. However, novel and imaginary 
approaches are needed. One could envision new antiarrhyth- 
mic agents that were site specific, preferentially traveling to 
arrhythmogenic areas, perhaps on the basis of new antibody- 
binding techniques (146,147). Drugs might concentrate in 
regions of myocardial damage that have been made unique 
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Figure 21. Actuarial probabilities of freedom from recurrence of 
symptomatic sustained ventricular tachyarrhythmia among all ran- 
domized patients (upper panel) and randomized patients with induc- 
ible sustained ventricular tachycardia at baseline (lower panel). 
Patients randomly assigned to the invasive approach are represented 
by the dashed lines. Those assigned to the noninvasive approach are 
represented by the solid lines. Vertical bars represent standard errors 
of the estimate. The numbers below each panel indicate the numbers 
of patients at risk at various points during the follow-up period. 
Reproduced with permission from Mitchell et al. (143). 
because of increased intracellular calcium concentrations, 
reduced membrane potential or other attributes. Drugs might 
uncouple arrhythmogenic areas (148) by acting specifically 
on gap junctions. 
Drugs could be developed that actually ablate areas of 
the myocardium, analogous to thyroid ablation by iodine- 
131. Several years ago we showed (149) that a chemical 
caustic applied to the left ventricular endocardium could 
ablate ventricular tachycardia. More recently, we demon- 
strated (150) that alcohol or phenol injected into the coro- 
nary artery perfusing the area of origin of a ventricular 
tachycardia could ablate the arrhythmia (Fig. 22). Injection 
of iced saline solution (151) or antiarrhythmic drugs (151a) 
into the relevant coronary artery may be used to verify 
appropriate catheter location (Fig. 23) before administration 
of phenol or alcohol. Thus. therapy to eliminate ventricular 
I? 
B. 
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Figure 22. Termination of ventricular tachycardia with 100% alco- 
hol injected through cannulation of an occluded coronary artery. In 
each panel, surface electrocardiographic (ECG) lead II. atrial elec- 
trogram (A), ventricular electrogram recorded from the region 
injected with alcohol (V,), arterial blood pressure (BP) and ventric- 
ular electrogram recorded from the normal area (V,) are arranged 
from top to bottom. Panel A, Ventricular tachycardia begins with a 
fusion beat after two sinus-initiated beats. Panel B, During ventric- 
ular tachycardia, I ml of 100% alcohol at room temperature was 
injected. Ventricular tachycardia was replaced by premature ven- 
tricular complexes and then sinus rhythm. Panel C, ST segment 
elevation and dimunition of V,4 electrogram are apparent. Panel D, 
This ECG recorded 20 min after alcohol injection demonstrates 
resolution of ST segment elevation, T wave inversion and sinus 
rhythm. This dog was unusual in that it was quite hypertensive 
before initiation of ventricular tachycardia (panel A), with return to 
the same blood pressure before ventricular tachycardia after alcohol 
injection. Study performed as reported in reference 150. 
tachycardia could be accomplished during selective coro- 
nary arteriography. Conceivably a similar approach could be 
used in patients with AV node reentrant tachycardia. A 
dilute alcohol injection into the AV node artery might be 
sufficient to alter the timing necessary for maintenance of the 
tachycardia without necessarily producing AV block requir- 
ing pacemaker treatment. 
Electrical therapeutic advances. These advances will pro- 
vide transvenous cardioverters-defibrillators that will have 
the multiple functions and programmable flexibility men- 
tioned earlier. They will more accurately differentiate ven- 
tricular from supraventricular tachycardias using electro- 
gram characteristics (1521, QRS duration, atria1 activity and 
biosensory end points. Nonthoracotomy implantation will 
become the rule (Fig. 17) (1531. Use of external automatic 
defibrillators in the home and public places will increase 
(154). 
Safer, more focused catheter ablation techniques em- 
ploying alternative energy sources will become available. 
An area ripe for further exploration. relatively uninvestiga- 
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Figure 23. Iced saline injection. Twelve lead electrocardiogram of 
ventricular tachycardia is shown in the top panel. Ten milliliters of 
iced saline (arrow, lower panel) injected into a distal septal perfora- 
tor coronary artery terminates the ventricular tachycardia (V,, lower 
panel). Study performed with James C. Dillon, MD and William M. 
Miles. MD. 
ted at present, is the electrical prevention of tachyarrhyth- 
mias through a variety of approaches (155,156). 
Surgical advances. Surgical therapies will continue to 
advance with improved mapping capabilities, particularly for 
ventricular tachycardias, and the development of new sur- 
gical approaches for treating patients who have recurrent or 
chronic atria1 fibrillation (157) and atria1 flutter (158). Recur- 
rent atria1 fibrillation is often a difficult management prob- 
lem, producing symptoms because of loss of atria1 systole, 
ventricular rate control and palpitation. Drug therapy fre- 
quently is ineffective for these patients. 
Improved risk stratification. Risk stratification to classify 
patients after myocardial infarction or after an episode of 
ventricular tachycardia or cardiac arrest due to ventricular 
fibrillation will improve to the point where screening proce- 
dures will accurately identify patients at increased risk of 
developing life-threatening arrhythmias before a serious 
event. As implantable devices improve, it is quite conceiv- 
able that a transvenous cardioverter-defibrillator will be 
inserted prophylactically in high risk patients, such as those 
with congestive heart failure, spontaneous ventricular 
arrhythmias and an abnormal signal-averaged ECG. 
Mechanisms and Pathogenesis of Arrhythmias 
The future offers an extraordinarily rich potential for a 
better understanding of the pathogenesis of cardiac arrhyth- 
mias. The last 20 years have witnessed an unprecedented 
burst of new knowledge about mechanisms of tachycardias 
in humans, derived primarily from catheter electrode tech- 
niques (159). Further new knowledge will come with the 
development of new tools that will allow us to gain additional 
Figure 24. Preoperative left lateral metaiodobenzylguanidine 
(MIBG) images showing homogeneous uptake (A). MIBG image 
obtained 9 weeks after latex injection, with a documented trans- 
mural myocardial infarction showing an anteroapical defect (arrows) 
(B). Simultaneous postoperative thallium image showing a small 
anterior wall defect (C) (arrow). White dot in left upper part of C is 
an artifact. Reproduced with permission from the American Heart 
Association, Inc. (95). 
information about the heart and arrhythmias in vivo (160). 
Monophasic action potential recordings may become useful, 
particularly for recording afterdepolarizations (10,11,32- 
34,36). New imaging techniques that will increase under- 
standing of biochemical changes in the myocardium involved 
in arrhythmias (161), discriminate scar from ischemia tissue 
(162) or clarify electrolyte and pH shifts (163) may be 
helpful. 
New imaging of myocardial innervation after infarction. 
Cardiac images of sympathetic innervaton may provide 
useful information. Metaiodobenzylguanidine (MIBG), an 
analogue of guanethidine, is taken up by sympathetic nerve 
terminals in a fashion similar to norepinephrine. Labeled 
with iodine-123, a gamma-emitter, MIBG can be used to 
provide a scintigraphic image of sympathetic nerve terminals 
in the heart (164). As demonstrated in the canine studies 
elaborated earlier (90-4) myocardial infarction creates sym- 
pathetic denervation of the myocardium apical to the site of 
myocardial infarction, which appears as a defect in the 
MIBG image (Fig. 24). Ten to 14 weeks later, reinnervation 
occurs in dogs. If an MIBG image of sympathetic innerva- 
tion is performed simultaneously with a thallium image (the 
latter to indicate areas of myocardial blood flow and cell 
viability), myocardium generating a normal thallium image 
but no MIBG uptake should represent viable but denervated 
areas of the ventricle (95). Such images representing appar- 
ent denervation have been found in patients after myocardial 
infarction. How important they are to the genesis of ventric- 
ular arrhythmias is still being explored (96). 
Microbiologic approaches. Subcellular approaches to un- 
derstanding physiology, often using the powerful tools of 
molecular biology, have captivated research interest in the 
last several years and promise to provide greater under- 
standing of many basic electrophysiologic concepts. To 
focus briefly on one small area, consider several events 
involved in the control of calcium in excitation-contraction 
coupling (Fig. 25). Calcium channels in the sarcolemma 
(outer cell membrane) reach a certain voltage that permits 
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Figure 25. Schematic diagram of calcium control. Calcium enters 
the cell one through a voltage-dependent calcium channel in the cell 
membrane (sarcolemma). The increase in cytosolic calcium concen- 
tration triggers calcium release two from the sarcoplasmic reticulum 
to interact with the contractile proteins. Calcium is then taken up by 
the sarcoplasmic reticulum three. See text for details. 
small amounts of calcium to enter the interior of the cell 
(cytosol) (165). This increase in cytosolic calcium then 
triggers a release of more calcium into the cytosol from the 
sarcoplasmic reticulum to interact with the contractile pro- 
teins. During diastole, calcium is pumped back into the 
sarcoplasmic reticulum with each cardiac cycle. Feet pro- 
teins connecting the T tubular system with the sarcoplasmic 
reticulum have been purified, and are the putative channels 
releasing calcium from the sarcoplasmic reticulum to the 
cytosol (166,167). The channel has a tetrameric appearance 
(Fig. 26) (166). The sarcoplasmic reticulum uptake pump is 
regulated by phosphorylation of the protein phospholamban 
(168). Because the sarcoplasmic reticulum membrane is 
inaccessible to standard electrophysiologic techniques, 
novel approaches to study calcium uptake and release across 
this membrane have been required. 
One wuy to do this is to create an artijicial memhrune 
thut allows the proteins to behave as channels (169). 
Purified phospholipids are painted onto a plastic mem- 
brane separating two chambers containing electrolyte solu- 
Figure 26. Schematic drawing of authors’ interpretation of electron 
micrographs of the calcium channel complex. Reproduced with 
permission from Lai et al. (166). 
tions. The membrane has a small hole in it. A channel 
protein (for example, the tetrameric feet protein or phospho- 
lamban) is added to the bath. and incorporates into the lipid 
bilayer. Activity of these channel proteins can now be 
recorded as discrete changes in the conductance of ions from 
one side of the membrane to the other because the feet 
proteins and phospholamban function as selective channels 
(Fig. 27). 
Conclusions 
New understanding of complex phenomena such as ionic 
currents and excitation-contraction coupling at the molecu- 
lar level using the approaches just outlined, studies of 
isolated “patches” of membrane removed from the cell to 
investigate single channel activity (170) advances in under- 
standing receptor physiology (171-173) and development of 
techniques to clone receptors and channels (174) have pro- 
vided new insights into subcellular and cellular function. 
However, these advances must be used to formulate hypoth- 
eses that can be tested in intact cells, organs and organisms. 
The excitement of molecular studies must not preempt the 
effort to understand the mechanisms in intact animals and 
humans. The behavior of isolated cells or pieces of cells, and 
now isolated proteins, indicates only what these substances 
are capable of doing, not necessarily what they are actually 
doing in vivo (4). Only by integrating the knowledge gener- 
ated from subcellular techniques with our knowledge of 
functionally intact systems complete with blood flow, auto- 
nomic responses and, yes. even a brain, can we begin to 
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understand why J.D. developed ventricular fibrillation after 
he learned that his mother had just died.* 
I thank David S. Bailie, MS, Donald A. Chilson, MD, Charles Fisch, MD, 
Jose Jalife, MD, Richard J. Kovacs, MD and Milton L. Pressler, MD for 
contributions to the manuscript. 
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